Compare ELWS & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELWS | HOTH |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4M | 18.0M |
| IPO Year | 2023 | 2019 |
| Metric | ELWS | HOTH |
|---|---|---|
| Price | $5.46 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 24.9K | ★ 219.2K |
| Earning Date | 12-31-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,083,071.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 145.52 | N/A |
| 52 Week Low | $1.64 | $0.66 |
| 52 Week High | $10.50 | $3.80 |
| Indicator | ELWS | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 55.46 | 39.99 |
| Support Level | $5.38 | $1.16 |
| Resistance Level | $6.11 | $1.25 |
| Average True Range (ATR) | 0.30 | 0.06 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 48.38 | 3.33 |
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).